[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100588032":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":10,"centralContacts":20,"locations":26,"responsibleParty":41,"collaborators":10,"id":44,"slug":10,"hasResults":45,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":49,"eligibilityCriteria":50,"healthyVolunteers":45,"sex":51,"minAge":52,"maxAge":53,"enrollmentInfo":54,"targetDuration":10,"studyType":57,"phases":10,"briefSummary":58,"conditions":59,"keywords":10,"overallStatus":28,"whyStopped":10,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":62,"startDateStruct":65,"completionDateStruct":67,"leadSponsor":69,"locationsCount":70},{"fullName":5,"class":6},"Shanghai Zhongshan Hospital","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"CHD patients undergoing target lesion PCI",null,"This study will enroll patients with CAD undergoing target lesion PCI, with appropriate non-target lesions near the target lesion, which served as the observed lesions",[13],"Diagnostic Test: Assessment of residual cholesterol and inflammatory risk factors",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":10},"DIAGNOSTIC_TEST","Assessment of residual cholesterol and inflammatory risk factors","The prespecifed risk factors include CRP, SAA, TNF-α, IL-6, MCP-1, Lp-PLA2, PCSK-9, Lp(a)",[9],[21],{"name":22,"role":23,"phone":24,"phoneExt":10,"email":25},"Chunfeng Dai, M.D.","CONTACT","86-021-64041990","dai.chunfeng@zs-hospital.sh.cn",[27],{"facility":5,"status":28,"city":29,"state":10,"zip":10,"country":30,"cosmosGeoPoint":31,"geoPoint":36,"contacts":37},"RECRUITING","Shanghai","China",{"type":32,"coordinates":33},"Point",[34,35],121.45806,31.22222,{"lat":35,"lon":34},[38,39],{"name":22,"role":23,"phone":24,"phoneExt":10,"email":25},{"name":22,"role":40,"phone":10,"phoneExt":10,"email":10},"PRINCIPAL_INVESTIGATOR",{"type":40,"investigatorFullName":42,"investigatorTitle":43,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"Chunfeng Dai","M.D.","100588032",false,"NCT06936111","REsiduAL rISk Under Intensive Lipid-lowering Therapy In Coronary Heart Disease","Effect of Residual Lipid and Inflammation Risk on Atherosclerotic Plaque Progression Under Intensive Lipid-lowering Therapy in Coronary Heart Disease","REALISTIC","Inclusion Criteria:\n\n* Diagnosed with CAD and PCI was successfully performed.\n* Presence of non-target lesions near the target lesion (more than 5mm proximal or distal), with stenosis of 20% to 50% and identifiable anatomical markers (e.g., branches, calcifications, stent edges).\n* 18 to 75 years old.\n* Written informed consent.\n\nExclusion Criteria:\n\n* Known autoimmune diseases, or taking immunosuppressive drugs for a long time before onset.\n* Known familial hypercholesterolemia.\n* Critical conditions (e.g., cardiogenic shock, acute heart failure).\n* Severe renal insufficiency (eGFR \\\u003C 30 mL \u002F(min·1.73m2)), or severe hepatic insufficiency (ALT or AST≥3 times the upper limit of normal).\n* Severe underlying diseases (such as end-stage malignancies), life expectancy \\\u003C 1 year.\n* Allergic to lipid-lowering medications.\n* Pregnant, or trying to become pregnant, and breastfeeding women.\n* Other conditions deemed unsuitable for inclusion by the researcher.","ALL","18 Years","75 Years",{"count":55,"type":56},900,"ESTIMATED","OBSERVATIONAL","Intensive lipid-lowering therapy is a cornerstone treatment for coronary heart disease (CHD). However, coronary plaque progression persists in a subset of patients even under intensive lipid-lowering therapy, which may be associated with residual lipid and inflammatory risks. Current research in this area remains largely confined to post hoc analyses of randomized controlled trials , with a notable scarcity of prospective follow-up cohorts. The investigators propose that establishing a prospective cohort will provide more authentic insights into the associations between residual risk factors and plaque progression. In this project, the investigators aim to establish a well-characterized CHD cohort with comprehensive data collection, good compliance, and an appropriate sample size. By focusing on non-target lesions within the target vessel and utilizing intravascular ultrasound (IVUS), the investigators will investigate the impact of residual lipid and inflammatory risks on plaque progression during intensive lipid-lowering therapy.",[60],"Coronary Heart Disease (CHD)","2026-01-30",{"date":63,"type":64},"2026-02-03","ACTUAL",{"date":66,"type":64},"2025-07-01",{"date":68,"type":56},"2027-07",{"name":5,"class":6},1]